Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical lymphoma, myeloma & leukemia·2026

Same author

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Blood advances·2026

Same author

Association Between Socioeconomic Inequalities and Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma.

JCO oncology practice·2026

Same author

CD56<sup>+</sup>/CD38<sup>+</sup> Neutrophils: Rapid and Specific Flow Cytometric Signature for Chronic Myeloid Leukemia.

Mediterranean journal of hematology and infectious diseases·2026

Same author

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience.

Haematologica·2026

Same author

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.

British journal of haematology·2026

Search research articles

Related Experiment Video

Updated: Feb 23, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Solitary Plasmacytoma.

Sara Grammatico¹, Emilia Scalzulli¹, Maria Teresa Petrucci¹

¹Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.

Mediterranean Journal of Hematology and Infectious Diseases

|September 13, 2017

Summary

Solitary plasmacytoma, a rare plasma cell disorder, includes bone and extramedullary types. Early diagnosis and distinguishing it from multiple myeloma are crucial for better patient outcomes.

Area of Science:

Hematology
Oncology

Background:

Solitary plasmacytoma is a rare localized plasma cell proliferation without systemic disease.
It presents as solitary bone plasmacytoma (SBP) or solitary extramedullary plasmacytoma (SEP).
SBP has a higher incidence and poorer prognosis than SEP due to a greater risk of evolving into multiple myeloma.

Purpose of the Study:

To review the current understanding of solitary plasmacytoma.
To highlight the importance of accurate diagnosis and differentiation from multiple myeloma.
To discuss current treatment strategies and prognostic factors.

Main Methods:

Literature review of solitary plasmacytoma.
Analysis of diagnostic advancements in distinguishing plasmacytoma from multiple myeloma.

Keywords:

Myeloma Osteolytic Lesions Radiotherapy Solitary Plasmacytoma

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Related Experiment Videos

Last Updated: Feb 23, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

Evaluation of treatment modalities including radiotherapy, surgery, and chemotherapy.

Main Results:

Advances in flow cytometry, molecular analysis, and imaging (MRI, PET) improve the exclusion of systemic disease.
Radiotherapy is the primary treatment, though optimal dosage and response rates are debated.
Limited data exists on the efficacy of novel agents, with most studies focusing on conventional chemotherapy in small patient cohorts.

Conclusions:

Accurate diagnosis is critical to avoid misclassification and ensure appropriate treatment.
Further research is needed to establish uniform prognostic factors and optimize treatment strategies, including the role of novel agents.